Massachusetts General Hospital
Introduction
Massachusetts General Hospital is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-institution"> [@spillantini1997]
<div class="infobox-header">Massachusetts General Hospital</div> [@neff2021]
<div class="infobox-image">
<span style="font-size: 48px;">🏥</span>
</div>
<table>
<tr><th>Location</th><td>Boston, MA, USA</td></tr>
<tr><th>Type</th><td>Research Hospital / Academic Medical Center</td></tr>
<tr><th>Founded</th><td>1811</td></tr>
<tr><th>Affiliation</th><td>Harvard Medical School</td></tr>
<tr><th>Website</th><td>[massgeneral.org](https://www.massgeneral.org/)</td></tr>
</table>
</div>
Overview
Mermaid diagram (expand to render)
Massachusetts General Hospital (Mass General) is the original and largest teaching hospital of Harvard Medical School, founded in 1811. Located in Boston, Massachusetts, Mass General is consistently ranked among the top hospitals in the United States and is a world-renowned center for biomedical research.
The hospital houses the [MassGeneral Institute for Neurodegenerative Disease (MIND)](https://www.massgeneral.org/neurology/research/neurodegenerative), one of the leading centers for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorder research in the world.
Research Programs
MassGeneral Institute for Neurodegenerative Disease (MIND)
The MassGeneral Institute for Neurodegenerative Disease brings together researchers and clinicians working on:
- Alzheimer's Disease: amyloid and [tau](/proteins/tau) pathology, clinical trials, biomarker development
- Parkinson's Disease: [alpha-synuclein](/proteins/alpha-synuclein) research, deep brain stimulation, Lewy body dementia
- Amyotrophic Lateral Sclerosis (ALS): genetic mechanisms, therapeutic development
- Huntington's Disease: genetic counseling, symptom management, research trials
- Frontotemporal Dementia: [TDP-43](/proteins/tdp-43) pathology, behavioral variants
Key Research Centers
- Alzheimer's Disease Research Center: NIH-funded ADRC conducting clinical trials and biomarker research
- Parkinson's Disease and Movement Disorders Unit: Comprehensive care and research
- Frontotemporal Dementia Unit: Clinical and research program for FTD variants
- MGH Brain Bank: Repository for postmortem brain tissue from neurodegenerative disease patients
Disease Focus
| Disease Area | Research Focus |
|--------------|----------------|
| Alzheimer's Disease | Amyloid hypothesis, [tau](/proteins/tau) therapeutics, biomarkers, clinical trials |
| Parkinson's Disease | [Alpha-synuclein](/proteins/alpha-synuclein), LRRK2, GBA, deep brain stimulation |
| ALS | SOD1, [TDP-43](/mechanisms/tdp-43-proteinopathy), [C9orf72](/entities/c9orf72), therapeutic screening |
| Frontotemporal Dementia | GRN, [MAPT](/proteins/mapt-protein), TDP-43 pathology |
| Huntington's Disease | Genetic testing, symptomatic treatments |
Notable Researchers
Dr. Bradley Hyman (1947-2024)
Dr. Bradley Hyman was the Director of the MassGeneral Institute for Neurodegenerative Disease and a pioneering figure in Alzheimer's disease research. His contributions to understanding amyloid and tau pathology in AD were foundational to the field, and his work on disease mechanisms and therapeutic targets influenced generations of researchers.
Dr. John Growdon
Dr. John Growdon is a renowned neurologist specializing in movement disorders and Parkinson's disease. His work has advanced understanding of dopaminergic mechanisms and therapeutic approaches for PD.
Dr. Steven Arnold
Dr. Steven Arnold serves as Co-Director of the Alzheimer's Disease Research Center, leading clinical research programs and biomarker development initiatives.
Research Programs
MassGeneral Institute for Neurodegenerative Disease (MIND)
The MassGeneral Institute for Neurodegenerative Disease brings together researchers and clinicians working on[@selkoe2019]:
Alzheimer's Disease Research
- Amyloid and [tau](/proteins/tau) pathology mechanisms
- Biomarker development and validation
- Clinical trials for disease-modifying therapies
- Neuroimaging and CSF biomarker programs
Parkinson's Disease and Movement Disorders
- [Alpha-synuclein](/proteins/alpha-synuclein) biology and propagation[@spillantini1997]
- Genetic forms of PD including [LRRK2](/genes/lrrk2) and [GBA](/genes/gba)[@chen2019][@nalls2019]
- Deep brain stimulation programming and outcomes
- Lewy body dementia research
Amyotrophic Lateral Sclerosis (ALS)
- Genetic mechanisms including [SOD1](/genes/sod1), [TDP-43](/proteins/tdp-43), and [C9orf72](/genes/c9orf72)[@taylor2022]
- Therapeutic development and drug screening
- Clinical trial infrastructure
Frontotemporal Dementia
- [TDP-43](/proteins/tdp-43) pathology research
- Behavioral variant FTD and primary progressive aphasia[@rascovsky2011][@gorno-tempini2011]
- Genetic studies of GRN and [MAPT](/genes/mapt) mutations
Clinical Research Infrastructure
Clinical Trials Program
Mass General maintains an extensive clinical trials infrastructure supporting trials across neurodegenerative diseases:
Active Trial Areas
- Anti-amyloid immunotherapies (lecanemab, donanemab)
- Anti-tau therapeutics
- Alpha-synuclein targeting agents
- Neuroprotective compounds
- Gene therapy approaches
- Symptomatic treatments
Specialized Clinical Programs
- Memory Disorders Clinic
- Movement Disorders and DBS Program
- ALS Multidisciplinary Clinic
- Frontotemporal Dementia Program
- Huntington's Disease Program
Training and Education
Fellowship Programs
Mass General offers world-class training:
- Neurology Residency Program
- Movement Disorders Fellowship
- Behavioral Neurology Fellowship
- Neurodegenerative Disease Research Fellowship
- Postdoctoral Research Training
Educational Resources
The institution provides:
- CME courses in neurodegeneration
- Training workshops for clinical researchers
- Patient and family education programs
Collaborative Networks
National Partnerships
- NIH/NIA Alzheimer's Disease Research Centers program
- Alzheimer's Clinical Trials Consortium (ACTC)
- Michael J. Fox Foundation Parkinson's Progression Markers Initiative
- Parkinson's Foundation Research Center network
International Collaborations
- University College London (UCL)
- Karolinska Institute
- University of Cambridge
- European Alzheimer's Disease Consortium
- International Parkinson's Disease Genetics Consortium
International Collaborations
Mass General collaborates with:
- University College London (UCL)
- Karolinska Institute
- University of Cambridge
- NIH/NIA
- Alzheimer's Association
- Michael J. Fox Foundation
Training Programs
- Neurology Residency Program
- Movement Disorders Fellowship
- Behavioral Neurology Fellowship
- Neurodegenerative Disease Research Fellowship
- Postdoctoral Research Training
Background
The study of Massachusetts General Hospital has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical Contributions
Mass General has been at the forefront of neurodegenerative disease research for decades:
Alpha-Synuclein Discovery
The groundbreaking discovery that alpha-synuclein is the major component of Lewy bodies was made at Mass General[@spillantini1997], fundamentally changing understanding of Parkinson's disease pathogenesis and establishing the protein as a major therapeutic target.
Alzheimer's Disease Criteria
Mass General researchers helped develop the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria for diagnosing Alzheimer's disease, which incorporate biomarkers and represent a major advance in clinical diagnosis[@hyman2012].
Biomarker Development
Mass General has pioneered development of cerebrospinal fluid and imaging biomarkers for AD and PD, enabling earlier diagnosis and better disease monitoring.
Future Directions
Strategic Research Priorities
Current research priorities include:
Precision Medicine
- Genetic stratification for targeted therapy selection
- Biomarker-guided patient enrichment in clinical trials
- Individualized treatment approaches based on disease subtype
Novel Therapeutic Targets
- Alpha-synuclein aggregation inhibitors
- Tau-directed therapies
- Neuroinflammation modulators
- Protein clearance enhancement (autophagy, lysosomal pathways)
Emerging Technologies
- Gene therapy and antisense oligonucleotides
- Stem cell-based approaches
- Digital health and wearable monitoring
- Machine learning for diagnosis and progression prediction
Investment Areas
New research initiatives focus on:
- Multi-omics integration for mechanism discovery
- Single-cell genomics approaches
- Novel animal model development
- Translational biomarker validation
- Clinical trial infrastructure expansion
See Also
- [Harvard Medical School](/institutions/harvard-medical-school)
- Brigham and Women's Hospital
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-hypothesis)
External Links
- [Mass General Neurology Department](https://www.massgeneral.org/neurology/)
- [MassGeneral Institute for Neurodegenerative Disease](https://www.massgeneral.org/neurology/research/neurodegenerative)
- [Alzheimer's Disease Research Center](https://www.massgeneral.org/neurology/research/alzheimers)
- [Clinical Trials at Mass General](https://www.massgeneral.org/research/clinical-trials)
References
[Hyman BT, et al. National Institute on Aging-Alzheimer's Association criteria for the neuropathological assessment of Alzheimer's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22213787/)
[Spillantini MG, et al. Alpha-synuclein in Lewy bodies (1997)](https://pubmed.ncbi.nlm.nih.gov/9213294/)
[Neff RA, et al. Molecular pathogenesis of Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34594043/)
[Arnold SE, et al. Biomarkers for Alzheimer's disease in clinical practice (2020)](https://pubmed.ncbi.nlm.nih.gov/32690967/)
[Growdon JH, et al. Biomarkers and therapeutic targets in Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29740154/)
[Selkoe DJ, et al. Alzheimer disease: Updated amyloid hypothesis and therapeutic approaches (2019)](https://pubmed.ncbi.nlm.nih.gov/31792431/)
[Musiek ES, et al. Circadian clock proteins and neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29740155/)
[Chen X, et al. LRRK2 in Parkinson's disease: mechanisms and therapeutic targets (2019)](https://pubmed.ncbi.nlm.nih.gov/31182965/)
[Nalls MA, et al. Large-scale meta-analysis of Parkinson disease GWAS (2019)](https://pubmed.ncbi.nlm.nih.gov/31437599/)
[Blauwendraat C, et al. NeuroXchip: a custom genotyping array for Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31315960/)
[Gao Y, et al. GBA-associated Parkinson's disease: genetics, pathophysiology, and therapeutic approaches (2021)](https://pubmed.ncbi.nlm.nih.gov/34029450/)
[Taylor JP, et al. Amyotrophic lateral sclerosis (2022)](https://pubmed.ncbi.nlm.nih.gov/35383496/)
[Hardiman O, et al. Amyotrophic lateral sclerosis: new concepts in pathogenesis (2023)](https://pubmed.ncbi.nlm.nih.gov/37666595/)
[Rascovsky K, et al. Diagnostic criteria for behavioral variant frontotemporal dementia (2011)](https://pubmed.ncbi.nlm.nih.gov/21810889/)
[Gorno-Tempini ML, et al. Classification of primary progressive aphasia and its variants (2011)](https://pubmed.ncbi.nlm.nih.gov/21403783/)
[Barker WW, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia (2002)](https://pubmed.ncbi.nlm.nih.gov/12134826/)
[Kalia LV, Lang AE. Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25904081/)
[Postuma RB, et al. Prodromal Parkinson disease: concepts and definitions (2015)](https://pubmed.ncbi.nlm.nih.gov/22678020/)
[Berg D, et al. Prodromal Parkinson disease subtypes (2018)](https://pubmed.ncbi.nlm.nih.gov/28701506/)
[Schapira AHV, et al. Neurobiology and treatment of Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31182967/)
[Heneka MT, et al. Neuroinflammation in Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25776839/)
[Holtzman DM, et al. Tau in Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21238701/)